Literature DB >> 9050832

Persistence in muscle of an adenoviral vector that lacks all viral genes.

H H Chen1, L M Mack, R Kelly, M Ontell, S Kochanek, P R Clemens.   

Abstract

Genetic correction of inherited muscle diseases, such as Duchenne muscular dystrophy, will require long term expression of the recombinant protein following gene transfer. We have shown previously that a new adenoviral vector that lacks all viral genes expressed both full-length dystrophin and beta-galactosidase in mdx (dystrophin-deficient) mouse muscle. We observed a significant histologic improvement of vector-transduced mdx muscle before the eventual loss of vector-encoded transgene expression. In this study, we investigated whether an immunological response against vector-encoded beta-galactosidase contributed to the loss of vector expression and affected vector persistence in muscle. Intramuscular vector injection in control normal mice resulted in an early and complete loss of beta-galactosidase expression accompanied by predominantly CD4+ and CD8+ lymphocytic infiltration and a significant loss of vector DNA. In contrast, intramuscular vector injection in lacZ transgenic mice resulted in persistent expression of beta-galactosidase for at least 84 days with no evidence of inflammation or significant loss of vector DNA. Our studies demonstrate that, in the absence of an immune response induced by beta-galactosidase expression, an adenoviral vector lacking all viral genes is stably maintained in muscle.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9050832      PMCID: PMC19970          DOI: 10.1073/pnas.94.5.1645

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  Quantitative polymerase chain reaction analysis of herpes simplex virus DNA in ganglia of mice infected with replication-incompetent mutants.

Authors:  J P Katz; E T Bodin; D M Coen
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

Review 2.  Development of adenovirus vectors for the expression of heterologous genes.

Authors:  K L Berkner
Journal:  Biotechniques       Date:  1988 Jul-Aug       Impact factor: 1.993

3.  Construction of plasmids that express E. coli beta-galactosidase in mammalian cells.

Authors:  G R MacGregor; C T Caskey
Journal:  Nucleic Acids Res       Date:  1989-03-25       Impact factor: 16.971

4.  Transcriptional regulation of the muscle creatine kinase gene and regulated expression in transfected mouse myoblasts.

Authors:  J B Jaynes; J S Chamberlain; J N Buskin; J E Johnson; S D Hauschka
Journal:  Mol Cell Biol       Date:  1986-08       Impact factor: 4.272

Review 5.  Gene therapy: adenovirus vectors.

Authors:  K F Kozarsky; J M Wilson
Journal:  Curr Opin Genet Dev       Date:  1993-06       Impact factor: 5.578

6.  Adenovirus as an expression vector in muscle cells in vivo.

Authors:  B Quantin; L D Perricaudet; S Tajbakhsh; J L Mandel
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

7.  Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells.

Authors:  R Kumar-Singh; J S Chamberlain
Journal:  Hum Mol Genet       Date:  1996-07       Impact factor: 6.150

8.  Gene therapy via primary myoblasts: long-term expression of factor IX protein following transplantation in vivo.

Authors:  Y Dai; M Roman; R K Naviaux; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

9.  Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice.

Authors:  T Ragot; N Vincent; P Chafey; E Vigne; H Gilgenkrantz; D Couton; J Cartaud; P Briand; J C Kaplan; M Perricaudet
Journal:  Nature       Date:  1993-02-18       Impact factor: 49.962

10.  The Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle.

Authors:  E E Zubrzycka-Gaarn; D E Bulman; G Karpati; A H Burghes; B Belfall; H J Klamut; J Talbot; R S Hodges; P N Ray; R G Worton
Journal:  Nature       Date:  1988-06-02       Impact factor: 49.962

View more
  45 in total

Review 1.  The promise and potential hazards of adenovirus gene therapy.

Authors:  L S Young; V Mautner
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

2.  Optimization of the helper-dependent adenovirus system for production and potency in vivo.

Authors:  V Sandig; R Youil; A J Bett; L L Franlin; M Oshima; D Maione; F Wang; M L Metzker; R Savino; C T Caskey
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

3.  Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases.

Authors:  C E Thomas; G Schiedner; S Kochanek; M G Castro; P R Löwenstein
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

4.  Novel role for E4 region genes in protection of adenovirus vectors from lysis by cytotoxic T lymphocytes.

Authors:  J M Kaplan; D Armentano; A Scaria; L A Woodworth; S E Pennington; S C Wadsworth; A E Smith; R J Gregory
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

5.  Restricting expression prolongs expression of foreign genes introduced into animals by retroviruses.

Authors:  V B Pinto; S Prasad; J Yewdell; J Bennink; S H Hughes
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

6.  Chromosomal integration pattern of a helper-dependent minimal adenovirus vector with a selectable marker inserted into a 27.4-kilobase genomic stuffer.

Authors:  M Hillgenberg; H Tönnies; M Strauss
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

7.  Cre levels limit packaging signal excision efficiency in the Cre/loxP helper-dependent adenoviral vector system.

Authors:  Philip Ng; Carole Evelegh; Derek Cummings; Frank L Graham
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

8.  An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus.

Authors:  D Maione; C Della Rocca; P Giannetti; R D'Arrigo; L Liberatoscioli; L L Franlin; V Sandig; G Ciliberto; N La Monica; R Savino
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

Review 9.  Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disorders.

Authors:  Pedro R Lowenstein; Donata Suwelack; Jinwei Hu; Xianpeng Yuan; Maximiliano Jimenez-Dalmaroni; Shyam Goverdhana; Maria G Castro
Journal:  Int Rev Neurobiol       Date:  2003       Impact factor: 3.230

10.  Development and characterization of novel empty adenovirus capsids and their impact on cellular gene expression.

Authors:  Jackie L Stilwell; Douglas M McCarty; Atsuko Negishi; Richard Superfine; R Jude Samulski
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.